Mineralys Therapeutics MLYS 深 滬
已收盤 05-08 16:00:00 美东时间
29.54
+0.190
+0.65%
華盛通- 最 高30.00
- 今 開29.12
- 成交量 89.49万股
- 最 低 28.5701
- 昨 收 29.35
- 總市值 243.56万
- 52周最高 47.65
- 市盈率 靜 --
- 換手率 1085.33%
- 52周最低 12.59
- 委 比 -31.58%
- 總股本 8.25万
- 歷史最高 47.65
- 量 比 0.64
- 振 幅 4.87%
- 歷史最低 5.85
- 每 手 1
- 風險率 10.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Mineralys Therapeutics 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.39亿美元，同比亏损缩窄7.1%
华盛资讯5月7日讯，Mineralys Therapeutics公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.39亿美元，同比亏损缩窄7.1%。
05-07 05:05
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced the FDA acceptance of its NDA for lorundrostat to treat hypertension, with a PDUFA target date of December 22, 2026. The company highlighted its strong progress in advancing lorundrostat, supported by five positive clinical trials demonstrating significant blood pressure reduction and favorable safety. Financially, the company reported $646.1 million in cash and investments as of March 2026, with reduced R&D expen...
05-06 20:05
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.
04-28 01:06
Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405
Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405 Mineralys Therapeutics Chief Medical Officer Rodman David Malcom sold 2,170 shares on April 9 at USD 27.38. Transaction followed exercise of 2,170 stock options at USD 16. Malcom held 76,140 shares directly after transactions. Discla
04-14 09:14
Mineralys Therapeutics announces annual shareholder meeting
Mineralys Therapeutics announces annual shareholder meeting Mineralys Therapeutics will hold its annual shareholder meeting online May 21, 2026. Shareholders will vote to elect three Class III directors for terms expiring at 2029 annual meeting. Meeting agenda also includes ratification of Ernst & Y
04-08 20:48
BUZZ-Immunic rises after board hire of MS drug veteran
BUZZ-Immunic rises after board hire of MS drug veteran ** Shares of biotech firm Immunic IMUX.O rise 5% to $1.08 premarket ** Co says it appointed Jon Congleton to its board; he helped launch Teva’s multiple sclerosis drug Copaxone in the United States ** Congleton has also served as CEO of Mineral
03-31 18:55
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics reported positive Phase 3 results for QTORIN™ rapamycin in treating microcystic lymphatic malformations, with plans to submit an NDA by late 2026, aiming to become the first FDA-approved therapy for this disease. The company also announced upcoming Phase 2 and 3 trials for QTORIN™ rapamycin in other rare skin conditions, including cutaneous venous malformations and angiokeratomas, as well as Phase 2 trials for QTORIN™ pitava...
03-31 11:30
